Immune Design, Scynexis partner for cGMP production of Glucopyranosyl Lipid A
GLA developed by Immune Design demonstrated ability to increase vaccine immunogenicity in humans in several clinical and preclinical studies. Immune Design president and chief executive officer Carlos Paya
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.